Reckitt is indeed after Merck’s consumer unit, and it’s ready for a close race

Carly Helfand As Reuters reported this weekend, Reckitt and Germany's Bayer have emerged as front-runners for the unit, which could go for $ 13.5 billion–or higher, ...

Regeneron R&D chief’s compensation shrinks, but still tops the chart

John Carroll FierceBiotech News

Transgene takes a hit as Novartis shreds $800M option deal

John Carroll France's Transgene took a hit this morning after the biotech announced that Novartis had decided to pass on its option for the therapeutic cancer vaccine TG4010. But ...

Pfizer’s post-megamerger cost-cutting record? 51,500 jobs in 7 years

Tracy Staton In the calm after yesterday's Pfizer-AstraZeneca deal storm, it's time to survey the potential fallout. Pfizer's aggressive strategy for avoiding taxes, totted ...

Sources: Bayer offers animal health biz, cash for Merck’s OTC unit

Eric Palmer When bidding wars get hot, that often springs information leaks. The latest is that there is some swap-and-shop haggling going on between Bayer and Merck over Merck's ...

Novartis grabs early FDA approval of lung cancer drug Zykadia

John Carroll After a quick march through the clinic, Novartis has won early FDA approval for the new "breakthrough" lung cancer drug ceritinib (or LDK378), which will now ...

Bristol-Myers targets neurodegenerative diseases in $725M deal to buy iPierian

John Carroll FierceBiotech News

More M&A: Forest snags Furiex for $1.1B as Meda stiff-arms Mylan’s $9B bid

Tracy Staton Pharma's M&A fever may be most obvious among the industry's biggest players, but smaller companies are making their own bids, transformational and otherwise. FiercePharma ...

Experts foresee premium pricing for overdose-fighting injector Evzio

Tracy Staton Amid fierce debate over hepatitis C drug costs, another example of potentially questionable pricing looms, The New York Times contends. The new anti-overdose injector, ...

On heels of an IPO, Concert’s kidney drug flops in PhII

John Carroll Just two months after raising $ 84 million from an upsized IPO, Concert Pharmaceuticals says that a key Phase II study of its lead drug–CTP-499–flopped on ...

Forest lands Furiex and expands GI business in $1.5B buyout deal

John Carroll Furiex has landed its big buyout deal. After nabbing promising late-stage data on a new drug for irritable bowel syndrome and virtually slapping a "for sale" ...

Why pay $100B for AstraZeneca? Let Pfizer’s CEO count the reasons

Tracy Staton Pfizer considers itself a megamerger expert. And it's hoping to prove that with another megadeal–a $ 100 billion-or-so buyout of AstraZeneca. After last week's ...
Page 1 of 512345
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS